ONC

BeOne Medicines Ltd. NASDAQ Listed Feb 2, 2016

Healthcare ·Medical - Pharmaceuticals ·US · beonemedicines.com

$313.32

After hrs $313.32 +0.00%

Mkt Cap $33.5B

52w Low $218.31 56.9% of range 52w High $385.22

50d MA $301.78 200d MA $320.59

P/E (TTM) 8.6x

EV/EBITDA 49.6x

P/B 7.3x

Debt/Equity 0.5x

ROE 6.6%

P/FCF 35.2x

RSI (14) —

ATR (14) —

Beta 0.54

50d MA $301.78

200d MA $320.59

Avg Volume 242.7K

About

BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established it…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 26, 2026	BMO	1.60	0.58	-63.8%	322.37	-1.2%	-1.7%	-2.5%	-7.9%	-7.2%	-9.1%	—
Nov 6, 2025	BMO	0.72	1.09	+51.4%	332.36	-5.1%	-3.7%	-1.0%	+3.4%	+13.6%	+10.8%	—
Aug 6, 2025	BMO	0.48	0.84	+75.0%	298.52	-0.4%	-0.1%	-3.5%	-2.9%	-3.5%	+3.0%	—
May 7, 2025	BMO	-0.71	1.22	+271.8%	232.25	+1.7%	+1.6%	-0.1%	+0.4%	-3.2%	-5.3%	—
Feb 27, 2025	BMO	-0.88	-1.43	-62.5%	278.38	-2.9%	-2.4%	-11.8%	-7.6%	-5.8%	-7.7%	—
Nov 12, 2024	BMO	-0.88	-1.15	-30.7%	193.64	+2.0%	+0.9%	-0.2%	-2.3%	-3.1%	-3.0%	—
Aug 7, 2024	BMO	-2.10	-1.15	+45.2%	176.73	+1.2%	+3.6%	+3.4%	+7.5%	+5.9%	+5.6%	—
Mar 31, 2024	BMO	—	-2.41	—	156.39	—	—	+1.8%	-2.0%	-2.8%	-4.4%	—
Dec 31, 2023	BMO	—	-25.53	—	180.36	—	—	-1.9%	+0.6%	-2.6%	-8.3%	—
Sep 30, 2023	BMO	—	2.01	—	179.87	—	—	-0.8%	-3.1%	-6.0%	-5.1%	—
Jun 30, 2023	BMO	—	-3.64	—	178.30	+0.3%	+1.4%	+7.4%	+6.2%	+6.3%	+8.0%	—
Mar 31, 2023	BMO	—	-3.34	—	215.53	+0.0%	-1.2%	-0.2%	-1.6%	+10.6%	+9.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 16	Jefferies	Downgrade	Buy → Hold	—	$284.05	$286.11	+0.7%	+2.0%	+1.2%	-0.6%	-0.5%	-3.1%
Feb 27	Barclays	Maintains	Overweight → Overweight	—	$322.37	$318.66	-1.2%	-1.7%	-2.5%	-7.9%	-7.2%	-9.1%
Feb 27	Truist	Maintains	Buy → Buy	—	$322.37	$318.66	-1.2%	-1.7%	-2.5%	-7.9%	-7.2%	-9.1%
Feb 27	RBC Capital	Maintains	Outperform → Outperform	—	$322.37	$318.66	-1.2%	-1.7%	-2.5%	-7.9%	-7.2%	-9.1%
Feb 27	Guggenheim	Maintains	Buy → Buy	—	$322.37	$318.66	-1.2%	-1.7%	-2.5%	-7.9%	-7.2%	-9.1%
Feb 4	Barclays	Maintains	Overweight → Overweight	—	$346.38	$348.79	+0.7%	+1.6%	+0.2%	+2.2%	+0.7%	+2.0%
Nov 18	RBC Capital	Maintains	Outperform → Outperform	—	$376.63	$362.46	-3.8%	-3.4%	-6.1%	-7.3%	-7.7%	-11.7%
Nov 10	Citigroup	Maintains	Buy → Buy	—	$319.97	$329.00	+2.8%	+2.9%	+7.4%	+18.0%	+15.1%	+14.3%
Nov 7	RBC Capital	Maintains	Outperform → Outperform	—	$332.36	$315.53	-5.1%	-3.7%	-1.0%	+3.4%	+13.6%	+10.8%
Nov 7	Citizens	Maintains	Market Outperform → Market Outperform	—	$332.36	$315.53	-5.1%	-3.7%	-1.0%	+3.4%	+13.6%	+10.8%
Oct 20	Morgan Stanley	Maintains	Overweight → Overweight	—	$316.42	$318.00	+0.5%	+0.7%	-0.2%	-0.9%	-2.0%	-1.8%
Oct 8	JP Morgan	Maintains	Overweight → Overweight	—	$341.62	$347.82	+1.8%	+2.8%	-1.7%	-6.3%	-4.3%	-6.1%
Aug 7	RBC Capital	Maintains	Outperform → Outperform	—	$298.52	$297.21	-0.4%	-0.1%	-3.5%	-2.9%	-3.5%	+3.0%
Aug 7	Guggenheim	Maintains	Buy → Buy	—	$298.52	$297.21	-0.4%	-0.1%	-3.5%	-2.9%	-3.5%	+3.0%
Jul 17	JP Morgan	Maintains	Overweight → Overweight	—	$279.16	$297.00	+6.4%	+4.0%	+5.5%	+4.6%	+5.9%	+5.6%
Jul 16	RBC Capital	Maintains	Outperform → Outperform	—	$269.70	$272.99	+1.2%	+3.5%	+7.7%	+9.2%	+8.2%	+9.6%
Jun 27	JP Morgan	Maintains	Overweight → Overweight	—	$254.49	$245.51	-3.5%	-5.2%	-4.9%	-3.7%	-4.0%	-3.5%
Jun 27	Morgan Stanley	Maintains	Overweight → Overweight	—	$254.49	$245.51	-3.5%	-5.2%	-4.9%	-3.7%	-4.0%	-3.5%
Jun 27	RBC Capital	Maintains	Outperform → Outperform	—	$254.49	$245.51	-3.5%	-5.2%	-4.9%	-3.7%	-4.0%	-3.5%
May 8	Guggenheim	Maintains	Buy → Buy	—	$232.25	$236.28	+1.7%	+1.6%	-0.1%	+0.4%	-3.2%	-5.3%
May 8	RBC Capital	Maintains	Outperform → Outperform	—	$232.25	$236.28	+1.7%	+1.6%	-0.1%	+0.4%	-3.2%	-5.3%
Apr 28	RBC Capital	Maintains	Outperform → Outperform	—	$244.90	$247.67	+1.1%	+1.9%	+2.0%	+6.1%	+4.4%	+4.4%
Apr 24	TD Securities	Maintains	Buy → Buy	—	$249.13	$257.88	+3.5%	+2.8%	-1.7%	+0.1%	+0.3%	+4.3%
Apr 21	JP Morgan	Maintains	Overweight → Overweight	—	$230.98	$231.28	+0.1%	-0.8%	+9.4%	+7.9%	+10.9%	+6.0%
Apr 16	Guggenheim	Maintains	Buy → Buy	—	$238.84	$235.00	-1.6%	-4.5%	-3.3%	-4.0%	+5.8%	+4.3%
Apr 10	Guggenheim	Maintains	Buy → Buy	—	$206.32	$218.64	+6.0%	+1.0%	+11.7%	+17.7%	+15.8%	+10.6%
Feb 28	Macquarie	Maintains	Outperform → Outperform	—	$278.38	$270.24	-2.9%	-2.4%	-11.8%	-7.6%	-5.8%	-7.7%
Feb 28	Citizens Capital Markets	Maintains	Market Outperform → Market Outperform	—	$278.38	$270.24	-2.9%	-2.4%	-11.8%	-7.6%	-5.8%	-7.7%
Nov 13	TD Cowen	Maintains	Buy → Buy	—	$193.64	$197.44	+2.0%	+0.9%	-0.2%	-2.3%	-3.1%	-3.0%
Oct 22	JP Morgan	Maintains	Overweight → Overweight	—	$219.92	$219.14	-0.4%	+0.3%	+0.5%	-2.6%	-3.2%	-1.2%
Aug 20	JP Morgan	Maintains	Overweight → Overweight	—	$192.50	$194.19	+0.9%	+0.9%	+2.8%	+1.6%	+0.7%	+3.5%
Aug 8	Citigroup	Maintains	Buy → Buy	—	$176.73	$178.80	+1.2%	+3.6%	+3.4%	+7.5%	+5.9%	+5.6%

Recent Filings

8-K · 2.02 !! High

BeOne Medicines Ltd. -- 8-K 2.02: Earnings Results

BeOne Medicines reported Q1 2026 financial results, providing investors with updated operational performance and financial health metrics for the quarter ended March 31, 2026.

May 6

Data updated apr 26, 2026 5:27pm · Source: massive.com